Salvia miltiorrhiza increases the expression of transcription factor Foxp3 in experimental murine colitis

Xu,Dekui; Yu,Hongbo; Yu,Qinggong; Wu,Simeng; Liu,Dongmei; Lin,Yan; Zhang,Ying; Zheng,Changqing

doi:10.3892/mmr.2014.1986

Salvia miltiorrhiza increases the expression of transcription factor Foxp3 in experimental murine colitis

Authors:
- Dekui Xu
- Hongbo Yu
- Qinggong Yu
- Simeng Wu
- Dongmei Liu
- Yan Lin
- Ying Zhang
- Changqing Zheng
View Affiliations

Affiliations: Department of Gastroenterology, Zhongshan Hospital of Dalian University, Dalian 116001, P.R. China, Department of Blood Bank, Shengjing Hospital of China Medical University, Shenyang, Liaoning 110004, P.R. China, Department of Gastroenterology, Shengjing Hospital of China Medical University, Shenyang, Liaoning 110004, P.R. China
Published online on: February 25, 2014 https://doi.org/10.3892/mmr.2014.1986
Pages: 1947-1951

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

Salvia miltiorrhiza (SM) is mainly used for the treatment of coronary heart disease in China, but previous studies demonstrated that it also shows anti‑inflammatory effects and the underlying mechanisms of these effects are not well understood. The present study aimed to investigate the effect of an injection of SM powder on the expression of transcription factor Foxp3 (Foxp3) in experimental colitis in mice. Mice were grouped and treated with SM powder for injection at the time of colonic instillation of trinitrobenzene sulfonic acid. Expression studies were performed by quantitative polymerase chain reaction and western blot analysis and histological studies were performed by hematoxylin and eosin staining. Myeloperoxidase activity was also tested for the evaluation of colitis. In the treated groups, the expression of Foxp3 mRNA and protein in the spleen were increased, the inflamed colonic lesions were relieved and the myeloperoxidase activity in the colon decreased significantly. Thus, it was demonstrated that SM exhibited its anti‑inflammatory by promoting Foxp3 expression. SM may be effective for the treatment of inflammatory disease, particularly for inflammatory bowel disease.

View Figures

View References

1	Braus NA and Elliott DE: Advances in the pathogenesis and treatment of IBD. Clin Immunol. 132:1–9. 2009. View Article : Google Scholar
2	Oliva-Hemker M and Fiocchi C: Etiopathogenesis of inflammatory bowel disease: the importance of the pediatric perspective. Inflamm Bowel Dis. 8:112–128. 2002. View Article : Google Scholar : PubMed/NCBI
3	Siminovitch KA: Advances in the molecular dissection of inflammatory bowel disease. Seminars Immunol. 18:244–253. 2006. View Article : Google Scholar : PubMed/NCBI
4	Cho JH and Weaver CT: The genetics of inflammatory bowel disease. Gastroenterology. 133:1327–1339. 2007. View Article : Google Scholar
5	Abdel-Hady M and Bunn SK: Inflammatory bowel disease. Current Paediatrics. 14:598–604. 2004. View Article : Google Scholar
6	Toruner M, Loftus EV Jr, Harmsen WS, Zinsmeister AR, Orenstein R, Sandborn WJ, Colombel JF and Egan LJ: Risk factors for opportunistic infections in patients with inflammatory bowel disease. Gastroenterology. 134:929–936. 2008. View Article : Google Scholar : PubMed/NCBI
7	Melmed GY, Ippoliti AF, Papadakis KA, Tran TT, Birt JL, Lee SK, Frenck RW, Targan SR and Vasiliauskas EA: Patients with inflammatory bowel disease are at risk for vaccine preventable illnesses. Am J Gastroenterol. 101:1834–1840. 2006. View Article : Google Scholar : PubMed/NCBI
8	Qin F and Huang X: Guanxin II (II) for the management of coronary heart disease. Chin J Integr Med. 15:472–476. 2009. View Article : Google Scholar : PubMed/NCBI
9	Bai A, Lu N, Guo Y and Fan X: Tanshinone IIA ameliorates trinitrobenzene sulfonic acid (TNBS)-induced murine colitis. Diges Dis Sci. 53:421–428. 2008. View Article : Google Scholar : PubMed/NCBI
10	Kang BY, Chung SW, Kim SH, Ryu SY and Kim TS: Inhibition of interleukin-12 and interferon-gamma production in immune cells by tanshinones from Salvia miltiorrhiza. Immunopharmacology. 49:355–361. 2000. View Article : Google Scholar : PubMed/NCBI
11	Yang XZ and Xue XP: Effects of Danshen injection on NF-κB activation of macrophages. J Liaoning Univ Tradit Chin Med. 4:184–185. 2007.
12	Dong WY, Hu GZ, Zhang B, Zheng CQ, Chen SN, Liu WL and Shi YD: Effects of twelve Chinese herbs on human regulatory T cell differentiation in vitro. World Chinese Journal of Digestology. 16:2770–2774. 2008.
13	Ye Y: Comparative study on the determination of salvianolic acids content by colorimetery and HPLC. J Zhejiang Univ Traditional Chinese Med. 30:350–351. 2006.
14	Neurath MF, Fuss I, Kelsall BL, Stüber E and Strober W: Antibodies to interleukin 12 abrogate established experimental colitis in mice. J Exp Med. 182:1281–1290. 1995. View Article : Google Scholar : PubMed/NCBI
15	Coquerelle C, Oldenhove G, Acolty V, Denoeud J, Vansanten G, Verdebout JM, Mellor A, Bluestone JA and Moser M: Anti-CTLA-4 treatment induces IL-10-producing ICOS+ regulatory T cells displaying IDO-dependent anti-inflammatory properties in a mouse model of colitis. Gut. 58:1363–1373. 2009.PubMed/NCBI
16	Bai A, Hu P, Chen J, Song X, Chen W, Peng W, Zeng Z and Gao X: Blockade of STAT3 by antisense oligonucleotide in TNBS-induced murine colitis. Int J Colorectal Dis. 22:625–635. 2007. View Article : Google Scholar : PubMed/NCBI
17	Krawisz JE, Sharon P and Stenson WF: Quantitative assay for acute intestinal inflammation based on myeloperoxidase activity. Assessment of inflammation in rat and hamster models. Gastroenterology. 87:1344–1345. 1984.PubMed/NCBI
18	Hibi T, Ogata H and Sakuraba A: Animal models of inflammatory bowel disease. J Gastroenterol. 37:409–417. 2002. View Article : Google Scholar
19	Tanchot C, Vasseur F, Pontoux C, Garcia C and Sarukhan A: Immune regulation by self-reactive T cells is antigen specific. J Immunol. 172:4285–4291. 2004. View Article : Google Scholar : PubMed/NCBI
20	Thorstenson KM and Khoruts A: Generation of anergic and potentially immunoregulatory CD25+CD4+ T cells in vivo after induction of peripheral tolerance with intravenous or oral antigen. J Immunol. 167:188–195. 2001.PubMed/NCBI
21	Tang Q and Bluestone JA: The Foxp3+ regulatory T cell: a jack of all trades, master of regulation. Nat Immunol. 9:239–244. 2008.
22	Hori S, Nomura T and Sakaguchi S: Control of regulatory T cell development by the transcription factor Foxp3. Science. 299:1057–1061. 2003. View Article : Google Scholar : PubMed/NCBI
23	Fontenot JD, Gavin MA and Rudensky AY: Foxp3 programs the development and function of CD4+CD25+ regulatory T cells. Nat Immunol. 4:330–336. 2003.
24	Khattri R, Cox T, Yasayko SA and Ramsdell F: An essential role for Scurfin in CD4+CD25+T regulatory cells. Nat Immunol. 4:337–342. 2003.PubMed/NCBI
25	Yagi H, Nomura T, Nakamura K, Yamazaki S, Kitawaki T, Hori S, Maeda M, Onodera M, Uchiyama T, Fujii S and Sakaguchi S: Crucial role of FOXP3 in the development and function of human CD25+CD4+ regulatory T cells. Int Immunol. 16:1643–1656. 2004.
26	Xu DK, Wu SM, Yu HB, Zheng CQ, Liu DM and Lin Y: Salvia miltiorrhiza inhibits the expressions of transcription factor T-bet (T-bet) and tumor necrosis factor α (TNFα) in the experimental colitis in mice. Afr J Biotechnol. 11:8323–8331. 2012.
27	Szabo SJ, Sullivan BM, Stemmann C, Satoskar AR, Sleckman BP and Glimcher LH: Distinct effects of T-bet in TH1 lineage commitment and IFN-gamma production in CD4 and CD8 T cells. Science. 295:338–342. 2002. View Article : Google Scholar : PubMed/NCBI